CEL-SCI

$17.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.61 (-3.32%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell CEL-SCI and other stocks, options, and ETFs commission-free!

About CVM

Cel-Sci Corporation, also called CEL-SCI, is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA. The listed name for CVM is Cel-Sci Corporation.

CEO
Geert R. Kersten
Employees
—
Headquarters
Vienna, Virginia
Founded
1983
Market Cap
707.64M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
837.28K
High Today
$19.23
Low Today
$17.76
Open Price
$18.69
Volume
607.39K
52 Week High
$40.91
52 Week Low
$8.10

CVM Earnings

-$0.37
-$0.25
-$0.12
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
-$0.21 per share

You May Also Like

CYCN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure